Innate Pharma S.A.
IPHYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $141 | $227 | $144 | $207 |
| - Cash | $54 | $66 | $70 | $71 |
| + Debt | $27 | $31 | $36 | $40 |
| Enterprise Value | $115 | $192 | $109 | $176 |
| Revenue | $5 | $0 | $12 | $21 |
| % Growth | 1,660.9% | -97.8% | -42.4% | – |
| Gross Profit | -$16 | $29 | -$17 | -$3 |
| % Margin | -322.2% | 10,634.8% | -135.5% | -14.6% |
| EBITDA | -$25 | -$21 | -$26 | -$10 |
| % Margin | -515.7% | -7,734.8% | -207.1% | -48.5% |
| Net Income | -$21 | -$25 | -$25 | -$9 |
| % Margin | -439.2% | -8,951.8% | -200.6% | -43.3% |
| EPS Diluted | -0.25 | -0.3 | -0.31 | -0.12 |
| % Growth | 16.7% | 3.2% | -158.3% | – |
| Operating Cash Flow | -$31 | -$10 | $3 | -$21 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$31 | -$10 | $3 | -$21 |